Inactive Instrument

News Matinas BioPharma Holdings Inc Other OTC

Equities

US5768101058

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 27	Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024
Mar. 27	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Matinas BioPharma Prices $10 Million Registered Direct Offering	Apr. 03	GL
Matinas BioPharma Prices $10 Million Registered Direct Offering	Apr. 03	AQ
Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	Mar. 27	GL
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	Mar. 27	AQ
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate, Expanded Use Access Program Achieve Complete Clinical Response	Mar. 25	AQ
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	Mar. 25	AQ
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	Mar. 25	GL
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	Mar. 25	AQ
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation	Mar. 25	CI
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response	Mar. 22	GL
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	Mar. 22	GL
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	Mar. 22	AQ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate, Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 27	AQ
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 26	GL
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 26	AQ
Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	Feb. 26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Matinas BioPharma Holdings Inc Other OTC

Equities

US5768101058

Summary

Filters